Cyclin-dependent kinase 4/6 inhibitors in granulosa cell tumors and their combination with hormonal therapy: a scoping review.

Authors

Renata Pacholczak-Madej, Radosław Łupkowski, Karolina Górniak, Mirosława Puskulluoglu

Published in

Frontiers in oncology. Volume 16. Pages 1844395. Epub Jun 26, 2026.

Abstract

Adult granulosa cell tumor (aGCT) is a rare ovarian malignancy with frequent late recurrences and limited systemic treatment options. Emerging evidence suggests that dysregulation of the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma (Rb) axis contributes to aGCT biology, while hormone receptor expression supports the potential role of endocrine therapy. We performed a scoping review to map available evidence on CDK4/6 inhibition in aGCT.
A literature search was conducted in PubMed/MEDLINE, Embase and Web of Science, complemented by searches of trial registries, conference abstracts and citation searching. Eligible reports included translational, preclinical and clinical studies addressing CDK4/6 pathway dysregulation or CDK4/6 inhibition in aGCT. Evidence on endocrine therapy was synthesized narratively to contextualize combination strategies.
Twenty-three reports were included. Translational and genomic studies showed recurrent abnormalities affecting cell-cycle regulation, including alterations in CDK inhibitors, Rb-associated signaling and other proliferation-related pathways. Preclinical studies demonstrated that CDK4/6 inhibition, particularly with abemaciclib, reduced cell viability and tumor growth in GCT models. Clinical evidence was limited to small retrospective case series, which suggested clinically meaningful disease control in a subset of patients with recurrent disease. An ongoing phase II trial is expected to provide the first systematic evaluation of this therapeutic strategy.
Available evidence supports CDK4/6 inhibition as a biologically plausible therapeutic strategy in aGCT. Although current clinical data remain limited, the combination of CDK4/6 inhibitors with endocrine therapy appears promising and warrants prospective evaluation.

PMID:
42434744
Bibliographic data and abstract were imported from PubMed on 11 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.